Wall Street analysts expect Illumina, Inc. (NASDAQ:ILMN) to announce $1.25 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for Illumina’s earnings, with estimates ranging from $1.17 to $1.40. Illumina reported earnings per share of $1.11 in the same quarter last year, which would suggest a positive year-over-year growth rate of 12.6%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, October 23rd.
On average, analysts expect that Illumina will report full year earnings of $5.46 per share for the current year, with EPS estimates ranging from $5.39 to $5.79. For the next fiscal year, analysts anticipate that the firm will report earnings of $6.17 per share, with EPS estimates ranging from $5.70 to $6.79. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Illumina.
Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, July 30th. The life sciences company reported $1.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.32. The company had revenue of $830.00 million during the quarter, compared to the consensus estimate of $786.88 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. Illumina’s revenue for the quarter was up 25.4% on a year-over-year basis. During the same period last year, the firm earned $0.82 EPS.
In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $311.84, for a total value of $3,118,400.00. Following the completion of the transaction, the senior vice president now directly owns 80,805 shares of the company’s stock, valued at approximately $25,198,231.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Robert S. Epstein sold 500 shares of the firm’s stock in a transaction on Monday, July 23rd. The shares were sold at an average price of $311.15, for a total transaction of $155,575.00. Following the completion of the transaction, the director now directly owns 6,139 shares of the company’s stock, valued at $1,910,149.85. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,483 shares of company stock valued at $17,702,063. Insiders own 0.54% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Kaizen Advisory LLC lifted its holdings in shares of Illumina by 161.0% during the 2nd quarter. Kaizen Advisory LLC now owns 368 shares of the life sciences company’s stock worth $103,000 after acquiring an additional 227 shares during the last quarter. Moneta Group Investment Advisors LLC lifted its holdings in shares of Illumina by 2,670.0% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 9,695 shares of the life sciences company’s stock worth $107,000 after acquiring an additional 9,345 shares during the last quarter. Sun Life Financial INC lifted its holdings in shares of Illumina by 152.5% during the 2nd quarter. Sun Life Financial INC now owns 399 shares of the life sciences company’s stock worth $111,000 after acquiring an additional 241 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its holdings in shares of Illumina by 3,192.3% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 428 shares of the life sciences company’s stock worth $120,000 after acquiring an additional 415 shares during the last quarter. Finally, Hall Laurie J Trustee lifted its holdings in shares of Illumina by 189.5% during the 2nd quarter. Hall Laurie J Trustee now owns 550 shares of the life sciences company’s stock worth $154,000 after acquiring an additional 360 shares during the last quarter. 89.91% of the stock is owned by institutional investors.
ILMN traded down $8.35 on Monday, hitting $313.10. The company’s stock had a trading volume of 1,482,906 shares, compared to its average volume of 1,087,215. The company has a market cap of $47.25 billion, a PE ratio of 78.28, a price-to-earnings-growth ratio of 2.66 and a beta of 0.97. Illumina has a 12 month low of $198.21 and a 12 month high of $372.61. The company has a current ratio of 2.74, a quick ratio of 2.44 and a debt-to-equity ratio of 0.22.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Further Reading: How do investors use RSI to grade stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.